Covid-19, Mean Platelet Volume, Platelet Destruction
Conditions
Brief summary
The study will aim to investigate the relation of platelet count (PLT), mean platelet volume (MPV) and platelet distribution width (PDW) with other acute phase reactant c-reactive protein(CRP) in Coronavirus(COVID-19). As a methodology, patients will be selected in records in one month from the online hospital system. Two groups will be divided before as need for mechanical ventilation or not. The latter comparison will be about three groups as an ambulatory follow-up, hospital follow-up, and intensive care unit follow-up. Parameters will be analyzed according to the groups.
Detailed description
In this study, as a methodology, patients diagnosed with PCR test through the online system created for COVID-19 patients will be included in the study. These patients will be divided into 3 groups as outpatient follow-up, hospital follow-up and follow-up with a mechanical ventilator in intensive care. In addition, patients who have completed the 14-day treatment period, which is considered as the turning point time of the world health organization by looking at the patients 3 times, every 5-7 days, which is the accepted incubation period, will be included in the study. In these patients, hemoglobin, leukocyte, platelet, MPV, PDW and CRP values will be examined for 3 weekly measurements. Changes in COVID-19 disease follow-up and treatment of MPV and PDW values, which have not been studied so far, will be investigated.
Interventions
DIAGNOSTIC_TESTPlatelet count, platelet, mean platelet volume and platelet distribution Width in COVID-19
Platelet count, platelet, mean platelet volume and platelet distribution Width in COVID-19
Sponsors
Konya Meram State Hospital
Study design
Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Patients diagnosed with COVID-19, both PCR tests and computed tomography, as well as control hemogram and CRP tests at one week intervals will be included.
Exclusion criteria
* Those with suspicion of COVID-19, those who do not perform hemogram and c-reactive protein tests 3 times with one week intervals, those who do not have standard drug treatment will be excluded from the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in PDW and MPV parameters | 3 weeks totally tests. | Expected increase or decrease in parameters according to the course of the disease |
Countries
Turkey (Türkiye)
Outcome results
None listed